Search Clinical Trials
Sponsor Condition of Interest |
---|
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous...
Mural Oncology, Inc
Cutaneous Melanoma
Mucosal Melanoma
This study observes the antitumor activity, safety, tolerability, PK, and
pharmacodynamics in patients with inoperable and/or metastatic melanoma expand
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma Type: Interventional Start Date: Sep 2021 |
EXHIT ENTRE Comparative Effectiveness Trial
Hennepin Healthcare Research Institute
Substance Use Disorder
Opioid Use Disorder, Moderate
Opioid Use Disorder, Severe
This study is a multi-site open-label randomized comparative effectiveness trial of a
28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual
(TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen
by an addiction consultation service... expand
This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service (ACS) and agreeing to initiate a medication for OUD (MOUD). Participants will be randomly assigned to XR-BUP or TAU to be received within 72 hours of anticipated hospital discharge. Follow up will occur at approximately 34, 90, and 180 days following hospital discharge. Type: Interventional Start Date: Aug 2021 |
Cortical-Basal Ganglia Speech Networks
Massachusetts General Hospital
Parkinson Disease
Essential Tremor
Dystonia
In this research study the researchers want to learn more about brain activity related to
speech perception and production. expand
In this research study the researchers want to learn more about brain activity related to speech perception and production. Type: Interventional Start Date: Oct 2020 |
TMS for the Treatment of Primary Progressive Aphasia
Massachusetts General Hospital
Logopenic Variant Primary Progressive Aphasia
Non-fluent Variant Primary Progressive Aphasia
Semantic Variant Primary Progressive Aphasia
Primary Progressive Aphasia (PPA) is a progressive syndrome in the family of Alzheimer's
disease and related disorders involving devastating language impairments caused by
selective neurodegeneration of the brain's language network. Unfortunately, there is no
treatment for PPA. An exciting possibility... expand
Primary Progressive Aphasia (PPA) is a progressive syndrome in the family of Alzheimer's disease and related disorders involving devastating language impairments caused by selective neurodegeneration of the brain's language network. Unfortunately, there is no treatment for PPA. An exciting possibility for treatment is non-invasive repetitive transcranial brain stimulation (rTMS), which induces electric currents in degenerating brain networks, making them in some cases more efficient. Therapeutic benefits from rTMS have been demonstrated when it is applied in many sequential sessions. For example, repeated sessions of rTMS to left dorsolateral prefrontal cortex (dlPFC) is approved by the US Food and Drug administration as a treatment for major depressive disorder. With respect to language, high frequency rTMS increases the response rate for picture naming in healthy individuals and in patients with Alzheimer's disease. Further, in a sham controlled study, Cotelli and colleagues demonstrated that in a group of 10 non-fluent PPA patients, high frequency rTMS over the left and right dlPFC improved the percent of correct responses for action naming. When rTMS was applied for five consecutive days in a sham controlled single case study, Finocchiaro and colleagues showed lasting improvements in language (up to 1 week) in a patient with non-fluent PPA. Trebbastoni and colleagues further showed the same lasting improvements in language (up to 1 week) in a patient with logopenic PPA. Recently, in a sham controlled single case study, Bereau and colleagues applied a more intense rTMS protocol for ten consecutive days and demonstrated significant linguistic improvements in a logopenic PPA patient that lasted for 1 month. These studies have contributed valuable insights into the potential use of rTMS in treating the language symptoms of PPA patients. Type: Interventional Start Date: Mar 2022 |
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022)...
Diwakar Davar
Melanoma Stage III
Melanoma Stage IV
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or
anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma. expand
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma. Type: Interventional Start Date: Jun 2020 |
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian...
Dana-Farber Cancer Institute
Endometrial Cancer
Ovarian Cancer
This research study is studying a combination of targeted therapies as a possible
treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous
ovarian cancer.
The drugs involved in this study are:
- Abemaciclib (also known as Verzenio™)
- Letrozole (also known... expand
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: - Abemaciclib (also known as Verzenio™) - Letrozole (also known as Femara®) - Metformin (also known as Glucophage®) - Zotatifin (also known as eFT226) Type: Interventional Start Date: Dec 2018 |
Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Colorectal Cancer
CRC
Pancreatic Ductal Adenocarcinoma
PDAC
Gastrointestinal Cancer
The purpose of this platform study is to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors
combined with Standard(s) of Care (SOC) or with novel agents.
The first three subprotocols include the following:
Subprotocol A: RMC-6236... expand
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The first three subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Type: Interventional Start Date: May 2024 |
Impact of Cognitive Behavioral Therapy on PTSD-CVD Link
Massachusetts General Hospital
Posttraumatic Stress Disorder
This is a pilot randomized controlled trial to assess the impact of a first-line
treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT)
versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this
study will test the hypothesis that CPT... expand
This is a pilot randomized controlled trial to assess the impact of a first-line treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT) versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this study will test the hypothesis that CPT reduces CVD risk through its effects on inflammation and autonomic function and that these changes are driven by changes in stress-related neural activity (SNA) Type: Interventional Start Date: Jul 2023 |
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
Massachusetts General Hospital
Anxiety Disorders
Psychotic Disorders
Depressive Disorder
Psychosocial Functioning
This research study aims to develop a brief group-based treatment called Resilience
Training for Teens, then to test how well it protects high school students with mild
symptoms of depression, anxiety, or having unusual feelings from developing mental
illnesses. expand
This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses. Type: Interventional Start Date: Mar 2024 |
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
Massachusetts General Hospital
Coronary Artery Disease
The goal of this randomized controlled trial is to assess the impact of disclosing a high
polygenic risk result for coronary artery disease on change in cardiovascular health over
one year. expand
The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year. Type: Interventional Start Date: Dec 2023 |
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine,...
Kura Oncology, Inc.
Acute Myeloid Leukemia
Mixed Lineage Acute Leukemia
Mixed Lineage Leukemia Gene Mutation
Mixed Phenotype Acute Leukemia
Refractory AML
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic
activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and
7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. expand
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. Type: Interventional Start Date: Jul 2023 |
Thoraflex Hybrid and Relay Extension Post-Approval Study
Vascutek Ltd.
Thoracic Diseases
Aortic Aneurysm
Aortic Dissection
Thoracic Aortic Aneurysm
Thoracic Aortic Dissection
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and
in combination with the RelayPro NBS stent-graft in the treatment of aortic disease
affecting the aortic arch and descending aorta with or without involvement of the
ascending aorta.
Patients who undergo treatment... expand
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site. Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed. Type: Observational Start Date: Mar 2023 |
Culturally Aware AET Non-Initiation Intervention
Massachusetts General Hospital
Breast Cancer
Survivorship
Treatment Compliance
Treatment Adherence
Treatment Refusal
The purpose of this study is to examine the feasibility and acceptability of a brief,
nurse-led intervention to support breast cancer survivors who have delayed initiation of
hormonal therapy or who have concerns about starting hormonal therapy. expand
The purpose of this study is to examine the feasibility and acceptability of a brief, nurse-led intervention to support breast cancer survivors who have delayed initiation of hormonal therapy or who have concerns about starting hormonal therapy. Type: Interventional Start Date: Jul 2022 |
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ALK-Abelló A/S
Peanut Allergy
This clinical research study investigates the safety and tolerability of a peanut
SLIT-tablet. expand
This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet. Type: Interventional Start Date: Sep 2022 |
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech
Boston University Charles River Campus
Stuttering, Developmental
Aphasia, Primary Progressive
Persistent developmental stuttering affects more than three million people in the United
States, and it can have profound adverse effects on quality of life. Despite its
prevalence and negative impact, stuttering has resisted explanation and effective
treatment, due in large part to a poor understanding... expand
Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder. Type: Interventional Start Date: Apr 2023 |
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening...
LimFlow, Inc.
Critical Limb Ischemia
Chronic Limb-Threatening Ischemia
Peripheral Arterial Disease
A prospective, single-arm, multi-center study designed to gather additional information
on the LimFlow System. expand
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System. Type: Interventional Start Date: Dec 2022 |
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
The reason for this study is to see if the study drug, selpercatinib, compared to placebo
is effective and safe in delaying cancer return in participants with early-stage
non-small cell lung cancer (NSCLC), who have already had surgery or radiation.
Participants who are assigned to placebo and stop... expand
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years. Type: Interventional Start Date: Dec 2021 |
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
This research study is studying a combination of drugs as a possible treatment for
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The names of the study drugs involved in this study are:
- obinutuzumab
- venetoclax
- acalabrutinib expand
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: - obinutuzumab - venetoclax - acalabrutinib Type: Interventional Start Date: Oct 2020 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors...
OncoC4, Inc.
Non Small Cell Lung Cancer
Advanced Solid Tumor
Metastatic Melanoma
Metastatic Head and Neck Carcinoma
Metastatic Renal Cell Carcinoma
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous
(IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as
single agent and in combination with pembrolizumab in participants with advanced or
metastatic solid tumors and non-small cell... expand
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers. Type: Interventional Start Date: Sep 2020 |
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Massachusetts General Hospital
Heart Failure With Normal Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Heart Failure, Right Sided
Heart Failure With Mid Range Ejection Fraction
Cardiovascular Risk Factor
In this single-center, longitudinal observational study, we will comprehensively examine
clinical characteristics, proteomic, metabolomic, genomic and imaging data to better
understand how different heart failure types may develop and progress over time. We will
evaluate distinct sub-groups of heart... expand
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure. Type: Observational [Patient Registry] Start Date: Apr 2016 |
Phenotyping Asthma for Bronchial Thermoplasty
Massachusetts General Hospital
Severe Asthma
This study will evaluate a new imaging technology, called optical coherence tomography
(OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is
a new treatment option for severe asthmatic patients. The aim of this study is to learn
more about how airways respond to... expand
This study will evaluate a new imaging technology, called optical coherence tomography (OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is a new treatment option for severe asthmatic patients. The aim of this study is to learn more about how airways respond to this new treatment. In the future the investigators hope OCT will aid clinicians in the initial assessment, management and long-term follow up of patients receiving bronchial thermoplasty. Type: Observational Start Date: May 2021 |
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and...
Michael Shy
Charcot Marie Tooth Disease
This is an observational longitudinal study to determine the natural history and
genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth
disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).
The investigators will also be determine the capability of the... expand
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window Type: Observational Start Date: Apr 2010 |
Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)
Massachusetts General Hospital
Mood Disorders
Anxiety Disorders
Psychotic Disorders
This study aimed to determine the feasibility and acceptability of delivering Resilience
Training in multi-user virtual reality. expand
This study aimed to determine the feasibility and acceptability of delivering Resilience Training in multi-user virtual reality. Type: Interventional Start Date: Sep 2020 |
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
Refractory Multiple Myeloma
Relapse Multiple Myeloma
Multiple Myeloma
This research is being done to see if the study drug, elranatamab, reduces the risk of
disease progression (worsening disease) after idecabtagene vicleucel in relapsed
refractory multiple myeloma. expand
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma. Type: Interventional Start Date: Mar 2024 |
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on...
Massachusetts General Hospital
Stress Disorders, Post-Traumatic
The proposed R21 project will attempt to further develop a novel intervention for
posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in
normal humans has shown that when a stable, consolidated memory is reactivated (i.e.,
retrieved) under appropriate conditions,... expand
The proposed R21 project will attempt to further develop a novel intervention for posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in normal humans has shown that when a stable, consolidated memory is reactivated (i.e., retrieved) under appropriate conditions, it reverts to an unstable state, a process referred to herein as deconsolidation. In such a state, the memory is susceptible to the action of various "amnestic" agents that may inhibit its reconsolidation, thereby weakening it. The β-adrenergic blocker propranolol (PPNL) possesses such amnestic properties. More recent research has found that in order to initiate deconsolidation, there must be a prediction error, or mismatch, between what is expected and what occurs when the memory is reactivated. Prior placebo-controlled, randomized clinical trials (PBO-RCT) from our laboratory have found that when propranolol is administered concomitant with the reactivation of a psychologically traumatic memory, the memory is weakened, as revealed by subsequent lower physiological (heart rate, skin conductance, facial electromyogram) responding during script-driven mental imagery. Clinical applicability was evaluated in a PBO-RCT, in which PTSD participants receiving propranolol underwent six weekly sessions of 10-20 min of "standard" (STD) traumatic memory reactivation stimulated by reading a narrative. At post-treatment, these participants showed a greater reduction of PTSD symptoms compared to participants who had taken PBO. The goal of the proposed study is to test whether intentionally incorporating innovative mismatch (MM) into traumatic memory reactivation can improve upon physiological responding during script-driven mental imagery. Participants will be randomized to one of 2 treatment arms: STD/PPNL and MM/PPNL. A baseline assessment will measure psychophysiological responsivity to script-driven mental imagery (target measure). PPNL will be administered 90-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions. In the MM condition, a different, unexpected mismatch (e.g., singing the narrative) will be incorporated into the reactivation. In the STD condition, the participant will read the narrative the same way each time. The focus of the R21 proposal will be to assess whether the MM/PPNL group shows lower subsequent physiological responses than the STD/PPNL group Type: Interventional Start Date: Jun 2023 |
- Previous
- Next